Farther Finance Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $123K | Buy |
379
+138
| +57% | +$45K | ﹤0.01% | 1650 |
|
|
2025
Q1 | $61.6K | Hold |
241
| – | – | ﹤0.01% | 1794 |
|
|
2024
Q4 | $56.8K | Buy |
241
+30
| +14% | +$7.07K | ﹤0.01% | 1595 |
|
|
2024
Q3 | $58.1K | Buy |
211
+103
| +95% | +$28.4K | ﹤0.01% | 1567 |
|
|
2024
Q2 | $26.3K | Buy |
108
+39
| +57% | +$9.51K | ﹤0.01% | 1680 |
|
|
2024
Q1 | $10.6K | Sell |
69
-25
| -27% | -$3.83K | ﹤0.01% | 1743 |
|
|
2023
Q4 | $18K | Buy |
94
+69
| +276% | +$13.2K | ﹤0.01% | 1365 |
|
|
2023
Q3 | $4.43K | Buy |
25
+4
| +19% | +$708 | ﹤0.01% | 1552 |
|
|
2023
Q2 | $3.99K | Buy |
21
+5
| +31% | +$950 | ﹤0.01% | 1508 |
|
|
2023
Q1 | $3.21K | Hold |
16
| – | – | ﹤0.01% | 1466 |
|
|
2022
Q4 | $3.8K | Buy |
+16
| New | +$3.8K | ﹤0.01% | 1260 |
|